Signal Hill is pleased to announce that its client Acurian, a leading full-service provider of clinical trial patient enrollment and retention solutions for the life sciences industry, has been acquired by Pharmaceutical Product Development, LLC, a leading global contract research organization (CRO) providing drug discovery, development, lifecycle management and laboratory services.
Pharmaceutical Product Development, LLC (PPD) announced it has acquired Acurian, a leading full-service provider of clinical trial patient enrollment and retention solutions for the life sciences industry.
“As the biopharmaceutical industry continues to face increasing challenges with the time and cost of drug development, PPD is committed to bringing innovation to the clinical development process to deliver efficiencies for our customers,” David Simmons, chairman and chief executive officer of PPD, said. “Acurian’s best-in-class approach to patient recruitment will be an excellent complement to PPD’s clinical development expertise. Acurian will enable PPD to provide clients industry-leading services that accelerate patient enrollment and support their strategies for data-driven feasibility, site selection and enrollment delivery.”